Skip to main content
Premium Trial:

Request an Annual Quote

No Q2 Revenues for Compugen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its second quarter, down from $800,000 a year ago.

The company's revenues comprise mainly of research fees and milestone and do not include government grants, which Compugen records as a reduction of R&D costs.

For the three months ended June 30, net loss totaled $2.2 million, or $.06 per share, up 146 percent from a net loss of $896,000, or $.03 per share a year ago.

R&D costs rose 23 percent year over year to $1.6 million from $1.3 million. The increase is due primarily to increased activities in Compugen's Pipeline Program, it said. The $1.6 million figure also does not include $455,000 in government grants it received during the quarter, which compares to $524,000 in government grants from a year ago.

SG&A costs were $2.2 million, up 204 percent from $724,000 a year ago.

Compugen ended the quarter with $23.7 million in cash, cash equivalents, and short-term bank deposits.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.